Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models

Jing Tian, Yuanzeng Min, Zachary Rodgers, Kin Man Au, C. Tilden Hagan, Maofan Zhang, Kyle Roche, Feifei Yang, Kyle Wagner, Andrew Z. Wang

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Chemoradiotherapy (CRT) with paclitaxel (PTX) and cisplatin (CP) is part of the standard of care for patients with locally advanced non-small cell lung cancer (NSCLC). Despite its high treatment intensity, many patients still develop local recurrence after treatment. Thus, there is a strong need to further improve CRT for lung cancer. One strategy is to co-deliver cytotoxic chemotherapy agents using biocompatible nanoparticles (NPs) which can limit off-target tissue toxicity and improve therapeutic efficacy. Herein, we report the development of dual-drug loaded nanoformulations that improve the efficacy of CRT for NSCLC by co-encapsulation of cisplatin (CP) and PTX in PLGA-PEG NPs. Mice bearing NSCLC xenografts were administered with dual-drug loaded NPs during CRT, which showed greater inhibition of tumor growth than free drug combinations or combinations of single-drug loaded NPs. These results indicate that using a NP co-delivery strategy for this common CRT regimen may improve clinical responses in NSCLC patients.

Original languageEnglish (US)
Pages (from-to)6049-6057
Number of pages9
JournalJournal of Materials Chemistry B
Volume5
Issue number30
DOIs
StatePublished - 2017
Externally publishedYes

ASJC Scopus subject areas

  • Chemistry(all)
  • Biomedical Engineering
  • Materials Science(all)

Fingerprint

Dive into the research topics of 'Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models'. Together they form a unique fingerprint.

Cite this